An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Sao Jose de Rio Preto, São Paulo 15091-000, Brazil
Akashi-shi, Hyōgo 6738558, Japan
Osakasayaha, Osaka 5898511, Japan
Takatsuki-shi, Osaka 5698686, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Sunto-gun, Shizuoka 4118777, Japan
Shimotsuke-shi, Tochigi 3290498, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Chuo-ku, Tokyo 1040045, Japan
Koto-ku, Tokyo 135-8550, Japan
Kita-gun, 7610793, Japan
Gangnam-gu, 06351, South Korea
L'Hospitalet Del Llobregat, 08908, Spain